Structural Formula Nalbuphine Hydrochloride (Nalbuphine 01)
Nalbuphine Hydrochloride Injection, Solution
Product Images NDC 0409-1463
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Nalbuphine Hydrochloride (NDC 0409-1463). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Novaplus Logo (Nalbuphine 02)
Principal Display Panel (10 mg/mL Ampule Label)
This is a prescription drug called Nalbuphine HCl Injection with a concentration of 10 mg/mL. It is intended for intravenous, intramuscular, or subcutaneous use. The medication should be protected from light. It is distributed by Hospira, Inc. in Lake Forest, IL, USA.*
Principal Display Panel (10 mg/mL Ampule Tray Label)
This text provides information about a 1mL single-dose ampule containing 10mg/mL of Nalbuphine Hydrochloride Injection. The product should be protected from light and kept in the tray until use. It is distributed by Hospira, Inc. under the Novaplus registered trademark of Vizient, Inc. The ampule contains nalbuphine HCI, sodium citrate, and citric acid as buffers, with sodium chloride added for tonicity adjustment. It may also contain NaOH and/or HCl for pH adjustment. The product is sterile, nonpyrogenic, and should be discarded after use. Storage instructions recommend keeping it at 20 to 25°C (68 to 77°F).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
